Navigation Links
Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine

GENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with migraine. The study achieved its primary objective, the absence of pain at 2 hours after dosing, with statistical significance, and also showed trends towards improvement in pain-free status and improvement of migraine pain at other time points. ADX10059 has already recently demonstrated a potential therapeutic benefit in a Phase IIa study in gastro-esophageal reflux disease (GERD), and is currently completing a Phase IIa study in anxiety.

ADX10059 is a potent, selective, negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5 NAM). Various pre-clinical pharmacology experiments have shown that glutamate is largely responsible for signal transmission in the neural circuit involved in migraine, and mGluR5 receptors are found at strategic points along the pathway. Inhibition of mGluR5 might therefore prevent the initiation of the migraine circuit, or interrupt it once established. For this initial exploratory study on the utility of an mGluR5 NAM in the management of migraine, an acute treatment paradigm was used.

The study was conducted in 129 migraine patients at opinion leader sites in the UK and Germany, according to the gold-standard design used for acute treatment of migraine. It comprised a multi-centre, double-blind, placebo-controlled comparison of a single dose of ADX10059 with placebo, to treat a single moderate or severe (IHS Grade 2 or 3) migraine headache, in an outpatient setting. Standard efficacy outcomes were used, with the primary efficacy variable being the proportion of patients pain-free (IHS Grade 0) 2 hours after dosing.

ADX10059 met the primary endpoint, showing a statistically significant higher number of patients pain-free 2 hours after dosing compared to placeb
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... YORK, July 4, 2011 ... market research report is available ... Global Pharmaceutical Industry Outlook ... Trends and Opportunities, Buyer Spend ...
... 2011 Simulated Environment Concepts (SMEV.PK), the manufacturer ... equipment, announced today that the Company has entered into what ... Management expects that much of the difficult items ... believes it is much more knowledgeable today about the auditing ...
Cached Medicine Technology:Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 2Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 3Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 4Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 5Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 6Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 7Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 8Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 9Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 10Global Pharmaceutical Industry Outlook Survey 2011-2012: Industry Dynamics, Market Trends and Opportunities, Buyer Spend and Procurement Strategies 11Simulated Environment Concepts Nears Audit Completion 2Simulated Environment Concepts Nears Audit Completion 3
(Date:4/14/2014)... Significant advances have been made in chemotherapy over the ... avoiding healthy tissues continues to be a major challenge. ... drug delivery, including the use of nanocarriers, or capsules, ... locations in the body. , The catch? These carriers ...
(Date:4/14/2014)... at Henry Ford Hospital reached a medical milestone April ... a novel way to access the heart. , Henry ... performing the unique procedure called transcaval valve replacement, which ... , Northern Michigan resident Viola Waller, 80, underwent Henry ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... their radiation treatment decisions leaves cancer patients feeling more ... distress around the experience, researchers from the Perelman ... report in the journal Cancer . , In ... Neha Vapiwala, MD , an associate professor in the ...
(Date:4/14/2014)... 2014 Popular web information on colorectal cancer is ... doesn,t address the appropriate risks to and concerns of ... suggests. , In a review of a dozen popular ... colorectal cancer screening were written beyond the recommended sixth-grade ...
Breaking Medicine News(10 mins):Health News:Nano shake-up 2Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3
... THURSDAY, Nov. 5 (HealthDay News) -- A program called ... says a U.S. government report. , Over three years, ... percent decrease in the number of students involved in ... report. The number of students who reported experiencing or ...
... adults, producing mild-to-moderate illness , THURSDAY, Nov. 5 (HealthDay ... the predominant flu strain worldwide, although it shows no ... mild-to-moderate symptoms in most people, the World Health Organization,s ... swine flu accounts for up to 70 percent of ...
... ... , ... Now there are some five-star reasons for Houston-area Medicare beneficiaries to choose KelseyCare ... its annual Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey, and KelseyCare Advantage ...
... 5 Attorneys from Dallas, Rasansky Law Firm ... on behalf of the mother of a 2-year-old girl who choked ... ago. The lawsuit includes claims that the day care,s owners quickly ... child,s death from showing up on a state licensing database. , ...
... , FAIRFIELD, Calif., Nov. 5 ChemSW is pleased ... The only Internet site that offers quick, confidential ... listed ChemSW as the top rated vendor overall in ... Despite an overall gloomy report where the customer satisfaction ...
... Nov. 5 Quantros, Inc., an industry leader in ... of care data surveillance solutions, today announced the acquisition ... a publicly traded company spun off from Cardinal Health ... not disclosed. , This latest addition to the ...
Cached Medicine News:Health News:School Violence Drops With Federal Program 2Health News:Swine Flu Virus Dominant Strain Worldwide: WHO 2Health News:Swine Flu Virus Dominant Strain Worldwide: WHO 3Health News:Local Medicare Advantage Plan Gets Five-Star Ratings from Medicare 2Health News:Local Medicare Advantage Plan Gets Five-Star Ratings from Medicare 3Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:ChemSW Rated Top Vendor Overall for Customer Satisfaction in Q3 2009 by VendorRate 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 2Health News:Quantros Acquires MediQual(TM) From CareFusion Corporation 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: